

Research Article

Jisuikang Promotes the Repair of Spinal Cord Injury in Rats by Regulating NgR/RhoA/ROCK Signal Pathway

Chengjie Wu^(b),^{1,2} Yuxin Zhou,² Pengcheng Tu,^{1,2} Guanglu Yang,^{1,2} Suyang Zheng,^{1,2} Yalan Pan,³ Jie Sun,^{1,2} Yang Guo ^(b),^{1,2} and Yong Ma ^(b),^{1,2}

¹Department of Traumatology and Orthopedics, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China ²Laboratory of New Techniques of Restoration & Reconstruction, Institute of Traumatology & Orthopedics, Nanjing University of Chinese Medicine, Nanjing, China

³Laboratory of Chinese Medicine Nursing Intervention for Chronic Diseases, Nanjing University of Chinese Medicine, Nanjing, China

Correspondence should be addressed to Yang Guo; drguoyang@126.com and Yong Ma; mayong@njucm.edu.cn

Received 10 June 2020; Revised 14 September 2020; Accepted 17 October 2020; Published 28 November 2020

Academic Editor: Arham Shabbir

Copyright © 2020 Chengjie Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Jisuikang (JSK) is an herbal formula composed of many kinds of traditional Chinese medicine, which has been proved to be effective in promoting the rehabilitation of patients with spinal cord injury (SCI) after more than ten years of clinical application. However, the mechanisms of JSK promoting nerve regeneration are yet to be clarified. The aim of this study was to investigate the effects of JSK protecting neurons, specifically the regulation of NgR/RhoA/ROCK signal pathway. The motor function of rats was evaluated by the BBB score and inclined plate test, Golgi staining and transmission electron microscope were used to observe the microstructure of nerve tissue, and fluorescence double-labeling method was used to detect neuronal apoptosis. In this study, we found that JSK could improve the motor function of rats with SCI, protect the microstructure (mitochondria, endoplasmic reticulum, and dendritic spine) of neurons, and reduce the apoptosis rate of neurons in rats with SCI. In addition, JSK could inhibit the expression of Nogo receptor (NgR) in neurons and the NgR/RhoA/ROCK signal pathway in rats with SCI. These results indicated JSK could improve the motor function of rats with SCI by inhibiting the NgR/RhoA/ROCK signal pathway, which suggests the potential applicability of JSK as a nerve regeneration agent.

1. Introduction

Spinal cord injury (SCI) is a disease with severe damage to the central nervous system, which has a complex pathological process and is difficult to recover in the later stage. The incidence of SCI is increasing year by year, so it is urgent to find a treatment to reduce the disability rate [1, 2]. However, traditional Chinese medicine has been concerned by more and more clinicians and scholars because of its advantages of multitargets and low side effects. The pathogenesis core of SCI is "deficiency of kidney governor, stasis of governor pulse, and dereliction of duty of cardinal command." JSK is a compound prescription of traditional Chinese medicine established under the guidance of this theory, which is very effective in the clinical treatment of SCI [3, 4].

In China, Buyang Huanwu decoction, as an important representative herbal formula for the treatment of SCI, has the function of restoring nerve and has a history of hundreds of years [5, 6]. However, the mechanism of Buyang Huanwu decoction is not clear, mainly related to thioredoxin system [7], glutamate [8], cAMP/CREB/RhoA signal pathway [9], apoptosis-related proteins [10], etc. JSK is formed by the addition and subtraction of Buyang Huanwu decoction, which is in line with the current clinical characteristics of SCI. After a large number of clinical tests, JSK has achieved satisfactory clinical efficacy, and part of its mechanism has been explained by animal and cell experiments [3, 4, 11–14]. Astragalus membranaceus, Salvia miltiorrhiza, and Ligustrazine are the main pharmacological components of JSK and have important therapeutic effects. Astragalus membranaceus has antioxidant and neuroprotective effects in

vivo, which provides the possibility for improving the symptoms of SCI [15–17]. *Salvia miltiorrhiza* has the effects of promoting blood circulation [18], antioxidation, and anti-inflammation [19], neuroprotection [20], etc. Ligustrazine can protect SCI by inhibiting inflammatory cytokines [21], inhibiting apoptosis [22, 23], and scavenging oxygen free radicals [24].

SCI is generally considered to be a devastating injury, and the growth of axons in the central nervous system is limited, so it could not be recovered. However, Aguayo et al. transplanted part of the peripheral nerve tissue into the transected spinal cord and found that the axons of the central nervous system could grow into the transplanted tissue, suggesting that neurons could grow after the adult central nervous system was damaged, but it was limited by the environment [25, 26]. Other studies have shown that the white matter homogenate of the central nervous system limits the growth of nerve axons [27], and oligodendrocytes and myelin sheath of the central nervous system can induce the collapse of the growth cone [28]. These proteins that inhibit axon growth are called myelin-associated inhibitors (MAIs), which mainly include neurite outgrowth inhibitor (Nogo), myelin-associated glycoprotein (MAG), and oligodendrocyte myelin glycoprotein (OMgp) [29]. Nogo receptor (NgR) can specifically bind to the above three kinds of MAIs and inhibit axonal regeneration [30], and the expression of NgR is directly related to the ability of central nervous cell regeneration [31], so NgR is considered to be one of the important targets for promoting axonal regeneration. In addition, the NgR/RhoA/ROCK signal pathway is an important way to inhibit neuronal axonal regeneration. Therefore, in this study, the development of NgR/RhoA/ ROCK signal pathway in rats with SCI in different time periods and the intervention effect of JSK were studied to explore part of the mechanism of improving SCI.

2. Methods and Materials

2.1. Chemicals. Prednisone (Tianjin Chemical Company, Tianjin, China) was dissolved and diluted in salt solution (final concentration is 0.3%), pentobarbital sodium (China Pharmaceutical Group Shanghai Chemical Reagents Co. LTD), and paraformaldehyde (Nanjing Fumace Biotechnology Co. LTD); JSK was composed of milkvetch root (30 g), Chinese angelica (12 g), red peony root (12 g), earthworm (10 g), *Cistanche deserticola* (10 g), *Salvia miltiorrhiza* (10 g), Szechwan lovage rhizome (10 g), peach seed (10 g), safflower (10 g), etc. (Pharmacy, Affiliated Hospital of Nanjing University of Chinese Medicine). JSK (crude drug 1.25 g/mL) was prepared by boiling, steam boiling, and concentration.

2.2. Animals. The animals used in this study were from the Animal Experimental Center of Nanjing University of Chinese Medicine, and the research scheme was approved by the Animal Ethics Committee of the affiliated Hospital of Nanjing University of Chinese Medicine. The experimental procedure follows the National Institutes of Health Guide

for the Care and Use of Laboratory Animals (Institute of Laboratory Animal Resources 1996). Eighty female SD rats with weight of 180~200 g were purchased from Qinglongshan Animal Breeding Farm in Nanjing, and the experimental animal license number was SYXK (SU) 2018-0049. Rats were kept in captivity at the Animal Experimental Institute of Nanjing University of Chinese Medicine (Nanjing, China) to eat and drink freely under controlled temperature and humidity.

2.3. SCI Rat Model. The acute SCI model based on the improved Allen method was used [32]. In short, all rats were anesthetized intraperitoneally with 1% pentobarbital sodium (50 mg/kg). The segment T9-11 of spinal cord was exposed surgically, and the segment T10 of spinal cord was hit with spinal cord percussion device (RWD Company). The weight and diameter of the falling object were 10 g and 2.5 mm, respectively, and the falling height and depth were 10 cm and 2 mm, respectively. The tension of the rat hind limbs was eliminated immediately, indicating that the model was established successfully. In the sham group, the spinal cord was exposed but not injured. The rats were randomly divided into four groups: sham group (intragastric infusion with normal saline, 20 mL/kg/d), model group (intragastric infusion with normal saline, 20 mL/kg/d), prednisone (PED) group (intragastric infusion with prednisone, 60 mg/kg/d), and JSK group (intragastric infusion with JSK, 25 g/kg/d). The rats were killed after the last intervention, and the samples were taken on the 7th, 14th, 21st, and 28th days after injury.

2.4. Basso, Beattie, and Bresnahan (BBB) Score. According to the observation of hindlimb movement, especially gait and coordination, the BBB test was carried out in the open field. Through double-blind and double-independent observation, all groups were evaluated on the 7th, 14th, 21st, and 28th days after operation [33].

2.5. Oblique Board Test. The oblique board test was carried out on all rats before operation and on the 1st, 7th, 14th, 21st, and 28th day after operation. The rats were placed on a rectangular oblique board perpendicular to the longitudinal axis of the oblique board. The oblique board was lifted, and the maximum angle was recorded at which the rats stayed on the board for more than 5 seconds. Each rat was tested for 3 times, and the average value was taken as the final result.

2.6. Golgi Staining. The spinal cord was fixed in 4% polyformaldehyde solution and cut into 2-3 mm thick tissue blocks after rinsing. The brain tissue blocks were completely immersed in Golgi staining solution and treated without light for 14 days. After being removed, it was dehydrated at 4°C in 15% sucrose solution and dehydrated for 1 day under the condition of avoiding light and dehydrated in 30% sucrose solution for 2 days. It was immersed in concentrated ammonia water for 45 minutes, distilled water for 1 minute, fixing solution treatment for 45 minutes, and distilled water washing for 1 minute. It was dehydrated in 30% sucrose solution for 2-3 days and cut into $100 \,\mu\text{m}$ frozen section, sealed by glycerin gelatin. Microscopic examination and image acquisition were carried out.

2.7. Observation by Using Transmission Electron Microscope. After the spinal cord was removed, it was fixed with electron microscope fixation solution at 4°C for 2–4 hours and rinsed with 1% osmic acid at 20°C for 2 hours. The organization in turn enters 50%-70%-80%-90%-95%-100%-100% alcohol-100% acetone-100% acetone, each time by 15 minutes. Acetone: 812 embedding agent = 1:1 was permeated for 2–4 hours; acetone: 812 embedding agent = 2:1 was permeated overnight, and pure 812 embedding agent was permeated for 5–8 hours, and then it was in 37°C oven overnight and polymerized at 60°C for 48 hours. It was cut into the ultrathin slices of 60–80 nm and double stained by uranium and lead, and the slices were dried at room temperature overnight. The images were collected and analyzed under the transmission electron microscope.

2.8. Fluorescent Double-Labeling Method of TUNEL and NeuN. Frozen sections of the spinal cord were fixed with 4% paraformaldehyde for 15 minutes and washed twice by PBS. 0.5% TritonX-100 was added to incubate for 5 minutes at room temperature. 5% fetal bovine serum was added at room temperature for 2 hours; NeuN first antibody of 1:1000 was added and incubated overnight at 4°C and washed 3 times. Fluorescent secondary antibody Alexa fluor 594 was added and incubated at room temperature and hidden from light for 1 hour. According to the instructions of the TUNEL kit, proper amount of detection solution was added sequentially and washed 3 times after incubation at 37°C for 1 hour. The plates were sealed with antifluorescence quenching solution and observed under the fluorescence inverted microscope.

2.9. Fluorescent Double-Labeling Method of NeuN and NgR. Frozen sections of spinal cord were fixed with 4% paraformaldehyde for 15 minutes, permeated with 0.5% Triton-100 for 10 minutes, and washed with PBS for 3 times. 5% goat serum was added at room temperature for 60 minutes. The first antibody NeuN (1:300) and NGR (1:300) was added and incubated overnight at 4°C. The second antibody Alexa fluor 594 and Alexa fluor 488 was added and incubated for 1 hour. After Dapi restaining, the plates were observed under fluorescence inverted microscope.

2.10. Immunohistochemistry. After the paraffin sections were dewaxed to water, the slides were immersed in citric acid antigen repair buffer, boiled water for antigen repair. They were transferred to 3% hydrogen peroxide solution and incubated in room temperature for 25 minutes. 3% BSA was dripped to cover the tissue evenly at room temperature for 30 minutes. The first antibody was dripped and incubated overnight at 4°C. HRP-labeled secondary antibody was dripped and incubated at room temperature for 60 minutes.

After drying, the slices were dripped with DAB chromogenic solution, then hematoxylin restaining was done, followed by hydrochloric acid alcohol differentiation, ammonia water returning to blue, and rinsed with running water. The slices were dehydrated and transparent in gradient alcohol and xylene, and the plates were observed under the microscope.

2.11. Western Blot Assay. The protein from the spinal cord was extracted and quantified by the BCA method. After adding buffer, the protein was boiled for 10 minutes and stored at -20° C to be tested. After preparing the glue, electrophoresis was carried out by 100 V constant voltage for 90 minutes, and PVDF membrane was used by 100 V for 60 minutes. 5% skimmed milk powder was added at room temperature for 2 hours, GAPDH and NgR, RhoA, and ROCK antibodies were prepared according to the ratio of 1:1000 and incubated overnight at 4°C. On the next day, the second antibody was prepared according to the proportion of 1:1000 and incubated at room temperature for 2 hours. An ECL developer was added, a gel imaging system was developed, and the ImageJ image analysis system was used to analyze the bands.

2.12. qRT-PCR. The RNA in the spinal cord was extracted with RNAiso for RNA (Takara, Japan) and then reverse transcribed with TaKaRa reverse transcription kit and frozen at -20° C. The sequence was found on Genbank, and primers were designed and synthesized in Shanghai Shenggong. GAPDH and NgR were detected by qPCR using TaKaRa TB Green TM Premix Ex Taq TM II PCR kit (Takara, Japan).

2.13. Statistic Analysis. SPSS 20.0 software was used for statistical analysis. The data were shown as mean \pm SD. One-way ANOVA and SNK-q test were used to analyze the differences among groups. The figures were edited by GraphPad Prism 8.0.2 software. A value of P < 0.05 was considered statistically significant.

3. Results

3.1. JSK Promotes the Recovery of Motor Function in Rats with SCI. The BBB score and oblique board test were carried out before operation and on the 1st, 7th, 14th, 21st, and 28th days after operation. The rats with SCI showed a gradual recovery of motor function, while JSK could gradually accelerate the process, and the effect was similar to the PED (Figure 1). The above results show that JSK has the potential to treat SCI.

3.2. JSK Can Improve the Microstructure of Neurons in Rats with SCI. The results of the transmission electron microscope showed that the microstructure of spinal myelin sheath and neurons were destroyed after SCI. JSK could alleviate the injury of myelin sheath and neurons after SCI, and at 7 d-28 d, it gradually improved (Figure 2). Golgi staining results showed that, after SCI, the dendrites were destroyed, the length became shorter, and the number of dendritic spines decreased. JSK could alleviate the injury of



FIGURE 1: JSK and PED promoted the recovery of motor function in rats with SCI. (a) The oblique board test showed that the motor ability of rats decreased after SCI, and the recovery of motor function could be accelerated after using JSK and PED. At the third week, the promoting effect of JSK was significantly different from the model group. (b) BBB score showed that the motor ability of rats decreased after SCI, and the recovery of motor function could be accelerated after using JSK and PED. At the third week, the promoting effect of JSK was significantly different from the model group. (b) BBB score showed that the motor ability of rats decreased after SCI, and the recovery of motor function could be accelerated after using JSK and PED. At the third and fourth weeks, the promoting effect of JSK was significantly different from that of the model group. The data were presented as mean \pm SD; n = 3/group, *P < 0.05, and **P < 0.01.



FIGURE 2: JSK improved the microstructure of neurons in rats with SCI. In the sham group, the shape of spinal myelin sheath was regular, like concentric circular arrangement, and it had a complete structure. The neurons were oval and had complete cell membrane structure, abundant organelles, more mitochondria and rough endoplasmic reticulum, no obvious rupture, or deletion of mitochondrial crest, and the morphology at 7 d–28 d was basically the same. In the model group, the shape of spinal myelin sheath was irregular, and the structure was disordered and incomplete, with partial breakage or deletion, local curl, and wrinkle. The number of neurons and mitochondria decreased, and there were dissolution of part of mitochondria, rupture and deletion of mitochondrial crest, and little change in morphology on 7 d–28 d. The myelin sheath shape of the spinal cord in the JSK group and the prednisone group was improved, the shape was more regular, the structure was more complete, the number of neurons and mitochondria was more, and the morphology of 7 d–28 d was greatly improved compared with the model group. *Note.* The red arrow indicates the myelin sheath and the green arrow indicates the mitochondria.



(a)





(b) FIGURE 3: Continued.



FIGURE 3: JSK improved the dendritic morphology of neurons in rats with SCI. (a) In the sham group, the morphology of spinal cord dendrites was regular, complete, and long, the dendritic spines arranged neatly, compact, and numerous, and the morphology at 7 d–28 d was basically the same. In the model group, the morphology of spinal cord dendrites was irregular, partially missing, and short, and the arrangement of dendritic spines was disordered and sparse, the number was less, and the morphological changes of 7 d–28 d were not much. In prednisone group and JSK group, the morphology of the spinal cord dendrites was improved, the shape was more regular, the structure was more complete, the length was longer, the dendritic spines were arranged neatly, the density was more uniform, the number was more, and the morphology of 7 d–28 d gradually improved. ((b), (c)) The length of dendrites and the number of dendritic spines in each group were statistically analyzed. The length of dendrites in the sham group was the longest and the number of dendritic spines was the most, while that in the model group was the shortest and the number of dendritic spines was the fewest. Compared with the sham group, the dendritic length and the number of dendritic spines in the model group were significantly decreased, and the dendritic length and the number of dendritic spine, and the data were presented as mean ± SD; n = 3/group, *P < 0.05, and *P < 0.05.

dendrites and dendritic spines after SCI, and the morphology of 7 d–28 d was gradually improved (Figure 3). The above results suggested that JSK could improve the microstructure of neurons (mitochondria, endoplasmic reticulum, dendritic spines, etc.) in rats with SCI.

3.3. JSK Can Reduce the Apoptosis Rate of Neurons in Rats with SCI. The double-labeling results of TUNEL and NeuN showed that the apoptosis rate of neurons increased after SCI, while JSK could reduce the apoptosis rate of neurons after SCI, and gradually improved between 7 d-28 d (Figure 4).

3.4. JSK Can Inhibit the Expression of NgR in Neurons of Rats with SCI. The double-labeling results of NeuN and NgR showed that the expression of NgR in neurons increased after SCI, but JSK could reduce the expression of NgR in neurons after SCI. On the 28th day, JSK significantly inhibited the expression of NgR in neurons (Figure 5).

3.5. JSK Can Inhibit the Expression of NgR/RhoA/ROCK in the Injured Area of Rats with SCI. Immunohistochemistry showed that the expression of NgR in the injured area of rats increased after SCI, but JSK could reduce the expression of NgR in the injured area of rats with SCI. Western blot and qRT-PCR showed that the expression of NgR/RhoA/ROCK in the injured area of rats increased after SCI, but JSK could reduce the expression of NgR/RhoA/ROCK in the injured area of rats with SCI. On the 28th day, JSK significantly inhibited the expression of NgR/RhoA/ROCK in the injured area of the spinal cord (Figure 6).

4. Discussion

It was estimated that the incidence of SCI in the United States was about 54 new cases per million people per year. Although the average life expectancy of patients with SCI has increased greatly in the past few decades, due to the aging of the population, the number of cases may continue to increase, and its serious complications can lead to higher economic burden [34]. However, there are few effective treatments for SCI, and the main treatment is still methylprednisolone, which only slightly improves the clinical results. Therefore, there is an urgent need to find a more effective method for the treatment of SCI. SCI belongs to central nervous system injury, and its self-repair ability is very poor, but it maintains the ability of nerve tissue remodeling and axonal plasticity. Its endogenous repair mechanism is mainly related to the properties of the neurons and glial cells, in particular, the local extracellular environment, and the specific inflammatory process caused by the lesion [34]. The current research direction of SCI mainly includes neutralization of myelin-derived inhibitors (e.g., anti-Nogo-antibodies [35]), downstream inhibition of related intracellular signaling pathways (Rho-GTPase signaling [36]), degradation of glial scar inhibitors (CSPG degradation by enzyme [37-39]), neuronal signal pathway (mTOR/PTEN [40]), and transplantation of neural progenitor cells and stem cells [41].

NgR is a GPI-anchored protein expressed in the neurons and axons of the central nervous system [31, 42]. It mediates the inhibitory effect of three kinds of MAIs by forming a receptor complex with p75 and MAIs [43]. When NgR specifically binds to MAIs, it is transmitted to RhoA by p75 and then acts on the effector ROCK to complete the signal



FIGURE 4: JSK could reduce the apoptosis rate of neurons in rats with SCI. (a) Representative images of Tunel and NeuN double-labeling results. (b) The results of statistical analysis showed that the apoptosis rate of neurons increased after SCI in rats but decreased after intervention of JSK. Compared with the sham group, the apoptosis rate of neurons in the model group increased significantly. Compared with the model group, JSK could significantly reduce the apoptosis rate of neurons. The data were presented as mean \pm SD; n = 3/group, *P < 0.05, and #P < 0.05.



FIGURE 5: JSK could reduce the expression of NgR in neurons of rats with SCI. (a) Representative images of double-labeling results of NeuN and NgR. (b) The results of statistical analysis showed that the expression of NgR in neurons increased after SCI in rats but decreased after intervention of JSK. Compared with the sham group, the expression of NgR in the model group was significantly increased, and compared with the model group, JSK could significantly reduce the expression of NgR in neurons. The data were presented as mean \pm SD; n = 3/group, *P < 0.05, and #P < 0.05.

transmission in the cell body, resulting in the collapse of the growth cone and inhibiting axonal regeneration [44–46]. The activation of RhoA is considered to be a key step for

MAIs to exert its inhibitory effect on axonal regeneration. Intervention of RhoA inactivating agent C3 transferase in vivo weakened the inhibitory effect of MAIs on axonal

Evidence-Based Complementary and Alternative Medicine







FIGURE 6: JSK could reduce the expression of NgR in the injured area of rats with SCI. (a) Representative images of immunohistochemistry. (b) Immunohistochemical statistics showed that, on the 28th day, the expression of NgR in the injured area of spinal cord increased but decreased after intervention of JSK. Compared with the sham group, the expression of NgR in the model group was significantly increased, and compared with the model group, JSK could significantly reduce the expression of NgR. (c) Representative images of western blot result. ((d), (e), (f), (g), (h), and (i)) The statistical results of western blot and qRT-PCR showed that, on the 28th day, the expression of NgR/RhoA/ROCK in the injured area of spinal cord increased but decreased after intervention of JSK. Compared with the sham group, the expression of NgR/RhoA/ROCK in the model group was significantly increased, and compared with the model group, JSK could significantly reduce the expression of NgR/RhoA/ROCK. NOTE: a is the model group, b is the prednisone group, c is the prednisone group, and d is the sham group. The data were presented as mean \pm SD; n = 3/group, *P < 0.05, and *P < 0.05.



FIGURE 7: Jisuikang, a Chinese herbal formula, promotes the repair of spinal cord injury in rats by regulating the NgR/RhoA/ROCK signal pathway.

growth [47]. In addition, treatment with Y27632, a competitive antagonist of ROCK synthesis of ATP, could still promote neuronal axonal growth in the presence of MAIs [48, 49]. The NgR/RhoA/ROCK signal pathway is an important way to inhibit neuronal axonal regeneration, and NgR is the key to this pathway. The development of the NgR/ RhoA/ROCK signal pathway in different periods after SCI should be studied. In this experiment, the motor function and the expression of NgR/RhoA/ROCK in rats with SCI were studied. Compared with the model group on the 28th day, the BBB score and oblique board test showed that JSK could promote the recovery of motor function in rats with SCI, Golgi staining, and transmission electron microscope which suggested that JSK could improve the microstructure of neurons (mitochondria, endoplasmic reticulum, dendritic

Evidence-Based Complementary and Alternative Medicine

spine, etc.) in rats with SCI. The double labeling of TUNEL and NeuN showed that JSK could reduce the apoptosis rate of neurons in rats with SCI, the double-labeling method of NeuN and NgR showed that JSK could inhibit the expression of NgR in neurons of rats with SCI; immunohistochemistry, western blot, and qRT-PCR all showed that JSK could inhibit the expression of NgR/RhoA/ROCK in the injured area of SCI rat (Figure 7).

In summary, the expression of NgR in the injured area of the spinal cord increased significantly and remained at a high level on the 7th day after SCI. However, on the 28th day, the expression of NgR/RhoA/ROCK in the PED group and JSK group was significantly lower than that in the model group, and JSK could significantly inhibit the expression of NgR/RhoA/ROCK in the injured area to promote nerve regeneration. This result is basically consistent with the results of Guo et al. [14, 50]. JSK can effectively inhibit the expression of NgR in the area of SCI, block the effect of myelin-derived nerve regeneration inhibitor and RhoA/ ROCK, improve the microenvironment of axon regeneration, and promote the repair of SCI. In addition, it is worth noting that the motor function of rats with SCI basically recovered continuously before 28 days, and JSK could accelerate this process. The expression of NgR decreased to a certain extent, but the middle part of the results showed that the expression of NgR increased abruptly, which may be due to the fact that NgR is not only the receptor of Nogo-A but also the receptor of MAG and OMgp, while MAG and OMgp may be activated with Nogo-A, thus increasing the expression of NgR. At the same time, the expression of NgR may be increased due to the regulation of other neuronal signal pathways, so the mechanism of multipathway needs to be further studied.

Data Availability

The data sets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors have declared that no conflicts of interest.

Acknowledgments

This article was supported by grants from the National Natural Science Foundation of China (81704100, 81573997, and 81973885), "Qing Lan Project" of Jiangsu University Funding Project (Su Teacher [2018] No. 12), and the project funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (Integration of Chinese and Western Medicine) [2018]87.

References

[1] E. Hayta and H. Elden, "Acute spinal cord injury: a review of pathophysiology and potential of non-steroidal antiinflammatory drugs for pharmacological intervention," Journal of Chemical Neuroanatomy, vol. 87, pp. 25-31, 2018.

- [2] N. B. Jain, G. D. Ayers, E. N. Peterson et al., "Traumatic spinal cord injury in the United States, 1993-2012," *JAMA*, vol. 313, no. 22, pp. 2236–2243, 2015.
- [3] M. Yong, W. Mao, and W. Jian-Wei, "28 cases of spinal cord injury treated with Jisuikang," *Liaoning Journal of Traditional Chinese Medicine*, no. 4, p. 309, 2017.
- [4] M. Yong, W. Mao, and W. Jian-Wei, "Jisuikang in the treatment of 19 cases of dysuria after spinal cord injury," *Jiangsu Journal of Traditional Chinese Medicine*, no. 4, p. 32, 2004.
- [5] L. Wang and D. M. Jiang, "Neuroprotective effect of Buyang Huanwu Decoction on spinal ischemia-reperfusion injury in rats is linked with inhibition of cyclin-dependent kinase 5," *BMC Complementary and Alternative Medicine*, vol. 13, p. 309, 2013.
- [6] C. Hao, F. Wu, J. Shen et al., "Clinical efficacy and safety of buyang huanwu decoction for acute ischemic stroke: a systematic review and meta-analysis of 19 randomized controlled trials," *Evidence-Based Complementary and Alternative Medicine*, vol. 2012, Article ID 630124, 10 pages, 2012.
- [7] L. Wang and D.-M. Jiang, "Neuroprotective effect of Buyang Huanwu decoction on spinal ischemia/reperfusion injury in rats," *Journal of Ethnopharmacology*, vol. 124, no. 2, pp. 219–223, 2009.
- [8] L.-D. Zhao, J.-H. Wang, G.-R. Jin, Y. Zhao, and H.-J. Zhang, "Neuroprotective effect of Buyang Huanwu decoction against focal cerebral ischemia/reperfusion injury in rats-time window and mechanism," *Journal of Ethnopharmacology*, vol. 140, no. 2, pp. 339–344, 2012.
- [9] P. Yang, A. Chen, Y. Qin et al., "Buyang huanwu decoction combined with BMSCs transplantation promotes recovery after spinal cord injury by rescuing axotomized red nucleus neurons," *Journal of Ethnopharmacology*, vol. 228, pp. 123– 131, 2019.
- [10] D. Xian-Hui, H. Xiao-Ping, and G. Wei-Juan, "Neuroprotective effects of the Buyang Huanwu decoction on functional recovery in rats following spinal cord injury," *The Journal of Spinal Cord Medicine*, vol. 39, no. 1, pp. 85–92, 2016.
- [11] P. Ya-Lan, G. Yang, Z. Long-Yun, Y. Wen-Chao, M. Yong, and H. Gui-Cheng, "Effects of Chinese herbal compound "Jisuikang" on phagocytosis of microglia and regeneration of injured neurons in co-culture system," *Chinese Journal of Immunology*, vol. 33, no. 11, pp. 1652–1657, 2017.
- [12] Y. Wen-Chao, W. Lei, Y. Ma, H. Gui-Cheng, Z. Long-Yun, and G. Yang, "Effect of Chinese herbal compound "Jisuikang" on engulfment of neuron debris by microglia," *The Journal of Medical Practice*, vol. 33, pp. 3359–3363, 2017.
- [13] J. W. Wang, J. F. Yang, Y. Ma et al., "Nogo-A expression dynamically varies after spinal cord injury," *Neural Regeneration Research*, vol. 10, no. 2, pp. 225–229, 2015.
- [14] Y. Guo, Y. Ma, Y. L. Pan, S. Y. Zheng, J. W. Wang, and G. C. Huang, "Jisuikang, a Chinese herbal formula, increases neurotrophic factor expression and promotes the recovery of neurological function after spinal cord injury," *Neural Regeneration Research*, vol. 12, no. 9, pp. 1519–1528, 2017.
- [15] Z. Jie-Mei and T. Kou-Ming, "Neuroprotective function of astragalus injection on treatment of rats with acute spinal cord injury," *Journal of Clinical Medical Practice*, vol. 18, no. 24, pp. 7–10, 2014.
- [16] R. Xian-Sheng, L. Xiang-Yang, Y. You-Geng, and X. Shen-Xiang, "Neuro-protective effect of astragalus root on

experimental injury of spinal cord in rats," *Chinese Journal of Clinical Rehabilitation*, vol. 7, pp. 31–33, 2003.

- [17] L. Shiqing, M. Yonggang, P. Hao et al., "Neuroprotective effects of Astragalus root on experimentally spinal cord injury in rats," *China Journal of Orthopaedics and Traumatology*, vol. 8, pp. 20–22, 2003.
- [18] J. Hu, S. Liu, Y. Yang, and D. Xu, "Effect of salvia miltiorrhiza on spinal cord blood flow and motor function of lower limb in rats with spinal cord injury," *Chinese Journal of Integrated Traditional and Western Medicine*, vol. 1, pp. 167–169.
- [19] X. Xiang and J. Shu, "Experimental study on free radical change after spinal cord injury and the effect of salvia miltiorrhiza on free radical," *Chinese Journal of Traumatology*, vol. 5, pp. 14–16.
- [20] L. Wei, Effect of Salvia Miltiorrhiza on Motor Function in Gray Matter of Acute Spinal Cord Injury in Rat and Its Mechanism, Fujian University of Traditional Chinese Medicine, Fuzhou, China, 2013.
- [21] L. Fan, K. Wang, Z. Shi, J. Die, C. Wang, and X. Dang, "Tetramethylpyrazine protects spinal cord and reduces inflammation in a rat model of spinal cord ischemia-reperfusion injury," *Journal of Vascular Surgery*, vol. 54, no. 1, pp. 192–200, 2011.
- [22] L. H. Fan, K. Z. Wang, B. Cheng, C. S. Wang, and X. Q. Dang, "Anti-apoptotic and neuroprotective effects of Tetramethylpyrazine following spinal cord ischemia in rabbits," *BMC Neuroscience*, vol. 7, p. 48, 2006.
- [23] X. Xiao, Y. Liu, C. Qi et al., "Neuroprotection and enhanced neurogenesis by tetramethylpyrazine in adult rat brain after focal ischemia," *Neurological Research*, vol. 32, no. 5, pp. 547–555, 2010.
- [24] Z. Zhang, T. Wei, J. Hou, G. Li, S. Yu, and W. Xin, "Tetramethylpyrazine scavenges superoxide anion and decreases nitric oxide production in human polymorphonuclear leukocytes," *Life Sciences*, vol. 72, no. 22, pp. 2465–2472, 2003.
- [25] S. David and A. Aguayo, "Axonal elongation into peripheral nervous system "bridges" after central nervous system injury in adult rats," *Science*, vol. 214, no. 4523, pp. 931–933, 1981.
- [26] P. M. Richardson, U. M. McGuinness, and A. J. Aguayo, "Axons from CNS neurones regenerate into PNS grafts," *Nature*, vol. 284, no. 5753, pp. 264-265, 1980.
- [27] T. Savio and M. Schwab, "Rat CNS white matter, but not gray matter, is nonpermissive for neuronal cell adhesion and fiber outgrowth," *The Journal of Neuroscience*, vol. 9, no. 4, pp. 1126–1133, 1989.
- [28] C. Bandtlow, T. Zachleder, and M. Schwab, "Oligodendrocytes arrest neurite growth by contact inhibition," *The Journal* of *Neuroscience*, vol. 10, no. 12, pp. 3837–3848, 1990.
- [29] Z. Cao, Y. Gao, K. Deng, G. Williams, P. Doherty, and F. S. Walsh, "Receptors for myelin inhibitors: structures and therapeutic opportunities," *Molecular and Cellular Neuroscience*, vol. 43, no. 1, pp. 1–14, 2010.
- [30] S. Ping, PirB Expression and Regulation on Axon Growth in Murine RGCs, Third Military Medical University, Chongqing, China, 2014.
- [31] X. Wang, S.-J. Chun, H. Treloar, T. Vartanian, C. A. Greer, and S. M. Strittmatter, "Localization of Nogo-A and Nogo-66 receptor proteins at sites of axon-myelin and synaptic contact," *The Journal of Neuroscience*, vol. 22, no. 13, pp. 5505–5515, 2002.
- [32] T. Khan, R. M. Havey, S. T. Sayers, A. Patwardhan, and W. W. King, "Animal models of spinal cord contusion injuries," *Laboratory Animal Science*, vol. 49, no. 2, pp. 161–172, 1999.

- [33] D. M. Basso, M. S. Beattie, and J. C. Bresnahan, "A sensitive and reliable locomotor rating scale for open field testing in rats," *Journal of Neurotrauma*, vol. 12, no. 1, pp. 1–21, 1995.
- [34] S. Soares, Y. von Boxberg, and F. Nothias, "Repair strategies for traumatic spinal cord injury, with special emphasis on novel biomaterial-based approaches," *Revue Neurologique* (*Paris*), vol. 176, 2020.
- [35] F. M. Bareyre, B. Haudenschild, and M. E. Schwab, "Longlasting sprouting and gene expression changes induced by the monoclonal antibody IN-1 in the adult spinal cord," *The Journal of Neuroscience*, vol. 22, no. 16, pp. 7097–7110, 2002.
- [36] M. A. Kopp, T. Liebscher, A. Niedeggen et al., "Small-molecule-induced Rho-inhibition: NSAIDs after spinal cord injury," *Cell and Tissue Research*, vol. 349, no. 1, pp. 119–132, 2002.
- [37] U. Milbreta, Y. von Boxberg, P. Mailly, F. Nothias, and S. Soares, "Astrocytic and vascular remodeling in the injured adult rat spinal cord after chondroitinase ABC treatment," *Journal of Neurotrauma*, vol. 31, no. 9, pp. 803–818, 2014.
- [38] E. J. Bradbury and L. M. Carter, "Manipulating the glial scar: chondroitinase ABC as a therapy for spinal cord injury," *Brain Research Bulletin*, vol. 84, no. 4-5, pp. 306–316, 2011.
- [39] J. W. Fawcett, M. E. Schwab, L. Montani, N. Brazda, and H. W. MÜller, "Defeating inhibition of regeneration by scar and myelin components," *Handbook of Clinical Neurology*, vol. 109, pp. 503–522, 2012.
- [40] K. Liu, Y. Lu, J. K. Lee et al., "PTEN deletion enhances the regenerative ability of adult corticospinal neurons," *Nature Neuroscience*, vol. 13, no. 9, pp. 1075–1081, 2010.
- [41] R. C. Assuncao-Silva, E. D. Gomes, N. Sousa, N. A. Silva, and A. J. Salgado, "Hydrogels and cell based therapies in spinal cord injury regeneration," *Stem Cells International*, vol. 2015, Article ID 948040, 24 pages, 2015.
- [42] A. Josephson, A. Trifunovski, H. R. Widmer, J. Widenfalk, L. Olson, and C. Spenger, "Nogo-receptor gene activity: cellular localization and developmental regulation of mRNA in mice and humans," *The Journal of Comparative Neurology*, vol. 453, no. 3, pp. 292–304, 2002.
- [43] G. Mei-ling and L. Xia-qing, "The roles and mechanism of myelin associated inhibitors," *Progress of Anatomical Sciences*, vol. 21, pp. 430–434, 2015.
- [44] T. Kubo, A. Yamaguchi, N. Iwata, and T. Yamashita, "The therapeutic effects of Rho-ROCK inhibitors on CNS disorders," *Therapeutics and Clinical Risk Management*, vol. 4, no. 3, pp. 605–615, 2008.
- [45] T. Kubo, K. Hata, A. Yamaguchi, and T. Yamashita, "Rho-ROCK inhibitors as emerging strategies to promote nerve regeneration," *Current Pharmaceutical Design*, vol. 13, no. 24, pp. 2493–2499, 2007.
- [46] T. Kubo and T. Yamashita, "Rho-ROCK inhibitors for the treatment of CNS injury," *Recent Patents on CNS Drug Discovery*, vol. 2, no. 3, pp. 173–179, 2007.
- [47] M. Lehmann, A. Fournier, I. Selles-Navarro et al., "Inactivation of Rho signaling pathway promotes CNS axon regeneration," *The Journal of Neuroscience*, vol. 19, no. 17, pp. 7537–7547, 1999.
- [48] P. Dergham, B. Ellezam, C. Essagian, H. Avedissian, W. D. Lubell, and L. McKerracher, "Rho signaling pathway targeted to promote spinal cord repair," *The Journal of Neuroscience*, vol. 22, no. 15, pp. 6570–6577, 2002.
- [49] B. Niederöst, T. Oertle, J. Fritsche, R. A. McKinney, and C. E. Bandtlow, "Nogo-A and myelin-associated glycoprotein mediate neurite growth inhibition by antagonistic regulation

Evidence-Based Complementary and Alternative Medicine

of RhoA and Rac1," *The Journal of Neuroscience*, vol. 22, no. 23, pp. 10368–10376, 2002.

[50] G. Yang, M. Yong, F. Cheng, Y. L. Pan, and G. C. Huang, "Effect of Jisuikang on Nogo-66 receptor NgR expression in rats with spinal cord injury," *Chinese Journal of Tissue En*gineering Research, vol. 20, no. 18, pp. 2622–2627, 2016.